The NeuroPrecision Surgical Control Suite is a medical-grade BCI platform developed by Lazarus Pharmaceuticals in collaboration with the GLMZ College of Surgical Sciences. The implant interfaces with the motor cortex and cerebellum simultaneously, using a 512-channel electrode array to intercept, filter, and re-amplify efferent motor signals before they reach the peripheral nervous system. A dedicated tremor-cancellation co-processor running at 4kHz samples hand and wrist motor commands in real time, applying adaptive inverse-frequency dampening to eliminate physiological tremor down to 0.003mm positional variance. The suite also includes a haptic-feedback upscaling layer that amplifies tactile sensation from surgical instruments by a factor of 40x, allowing surgeons to detect tissue resistance gradients that are imperceptible to unaugmented practitioners. A secondary neural thread handles intraoperative AR overlay, projecting patient vitals, imaging data, and instrument telemetry directly onto the surgical field as perceived by the user.

The NeuroPrecision is the de facto standard implant for licensed surgeons operating within GLMZ's Tier 3 and 4 hospital networks, particularly those affiliated with Lazarus Pharmaceuticals' own MedCenter chain. First-year surgical residents are frequently issued the implant on deferred-payment employer plans, with the understanding that the hardware includes a soft compliance lock — surgeons who leave Lazarus-affiliated institutions within five years of implantation face a licensing throttle that reduces tremor-cancellation fidelity to 60% until the device is re-keyed by a certified Lazarus technician. This practice is widely criticized by independent medical ethicists but remains technically legal under GLMZ's Professional Tools Retention Statute. Among surgical staff, the implant is affectionately called 'Lazarus Locks' — both for the performance it provides and for the contractual chains it represents.